<DOC>
	<DOCNO>NCT01514838</DOCNO>
	<brief_summary>The purpose study assess efficacy ASP1941 base change HbA1C well safety Asian subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety ASP1941 Asian Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This multi-center , active-controlled , double-blind , double-dummy , parallel-group comparative study . After screen period follow placebo run-in period single-blind condition , subject randomize either ASP1941 acarbose group . Subjects take study drug double-blind condition treatment period . After completion study drug administration , follow-up period provide .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>diagnose type 2 diabetes mellitus patient least 12 week study stable diet exercise program least 6 week study hypoglycemic agent nonnaïve subject , subject receive single hypoglycemic agent lowdose dual combination therapy BMI 20.0 45.0 kg/m2 hypoglycemic agent nonnaïve subject , subject HbA1c value 6.8 10.0 % screening AND HbA1c value 7.0 10.0 % , inclusive , runin period hypoglycemic agent naïve subject , subject HbA1c value 7.0 10.0 % , inclusive , runin period type 1 diabetes mellitus proliferative diabetic retinopathy receive insulin within 12 week prior study history clinically significant renal disease ( ) significant dysuria cause neurogenic bladder benign prostate hypertrophy etc . urinary tract infection genital infection continuous use systemic corticosteroid , immunosuppressant , loop diuretic history cerebrovascular attack , unstable angina , myocardial infarction , angioplasty , serious cardiac disease within 12 week prior study severe infection , serious trauma , perioperative subject know suspected hypersensitivity ASP1941 , acarbose alphaGI history treatment ASP1941 participate another clinical study , postmarketing study medical device study within 12 week study serum creatinine value exceed upper limit normal range urinary microalbumin/urinary creatinine ratio &gt; 300 mg/g</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>ipragliflozin</keyword>
	<keyword>plasma glucose</keyword>
	<keyword>urine glucose</keyword>
</DOC>